H2020Individual fellowship2021–2023

SHOXY · Tracing novel androgen pathways: deciphering the role of 16α-hydroxylation in human fetal biology

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2021-09-01 → 2023-08-31
EU contribution
€191,149
Participants
1
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

Tracing novel androgen pathways: deciphering the role of 16α-hydroxylation in human fetal biology

Steroid hormones play crucial roles in human fetal development as they bind and activate receptors which regulate key biological processes. These steroid hormones are also important after birth. During fetal development, a specific class of steroid hormones, termed androgens, are produced by the fetal adrenal and metabolised by the fetal liver and placenta. This biological route from the fetal adrenal through the fetal liver to the placenta is especially important, as an imbalance in androgen levels are implicated in endocrine-related disorders and diseases that present in the fetal and neonatal stages. In the fetal liver, an enzyme termed cytochrome P450 3A7, CYP3A7, catalyses the production of unique hydroxylated androgens. This same process is also mediated by CYP3A4 in neonates, as a switch from the predominant CYP3A7 to CYP3A4 activity occurs after birth, and while both hepatic enzymes metabolise androgens, only a few downstream hydroxylated androgen metabolites are currently known. The project “Tracing novel androgen pathways in human fetal biology: SHOXY” aimed to identify novel hydroxylated androgens and to characterise their metabolic pathway in human fetal biology. The characterization of these androgens and their downstream metabolites could prove integral to our understanding of the transition from the fetal to the neonatal stage and endocrine-related disorders that present at these stages. Ultimately, this project permitted an in-depth investigation into the hepatic metabolism of androgens specific to human fetal development, with an expected far-reaching impact on fetal and neonatal endocrinology. The scientific objectives of this Marie Skłodowska-Curie Action (MSCA) were to investigate (a) the biosynthesis of hydroxylated androgens by hepatic CYP3A enzymes; (b) the efficiency of these conversions by CYP3A7 compared to CYP3A4; and (c) the conversions in in vitro cell models and systems. The overarching goal of this action was to combine steroid science, protein chemistry and analytical chemistry to describe the role of androgens in fetal development! The training objectives of this MSCA were to (a) enhance the bioinformatic and analytical skills of the fellow, together with the networking skills of the fellow through the establishment of national and international collaborations; and (b) transfer the knowledge of adrenal steroidogenesis and mass spectrometric analysis of steroid metabolites from the fellow to the host institution, in the form of establishing analytical methods.

Data: CORDIS, © European Union

Project objective

Steroid hormones, produced by the fetal adrenal, are metabolised by the fetal liver and placenta thereby regulating fetal development. Consequently, these steroids are also implicated in endocrine-related disorders and diseases that present in the fetal and neonatal stage. The major fetal liver cytochrome P450 enzyme, CYP3A7, catalyses the production of 16α-hydroxy-dehydroepiandrosterone (16α-hydroxy DHEA) leading to the biosynthesis of the 16α-hydroxy estrogen of pregnancy, estriol, in the placenta. This 16α-hydroxylation is also mediated by CYP3A4 in neonates, as a switch from the predominant CYP3A7 to CYP3A4 expression occurs after birth. Both enzymes, together with CYP3A5 (expressed in adult livers) are capable of hydroxylating steroid substrates on C16 producing metabolites in the fetal and neonatal stages. Importantly, the major adrenal steroid, 11β-hydroxyandrostenedione (11OHA4), a C11-oxy androgen, is produced in the fetal adrenals and circulatory levels have been quantified at birth. The chemical structure of 11OHA4, possessing no moiety on C16, allows it to be hydroxylated by CYP3A enzymes —producing novel downstream 16α-hydroxylated metabolites. While the contribution of 16α-hydroxy DHEA to fetal biology has been widely reported, the contribution of 16α-hydroxy C11-oxy androgens has not, to date, been characterised. Moreover, these metabolites have not been structurally identified. I hypothesise that C11-oxy androgens are catalysed by CYP3As, producing novel 16α-hydroxy C11-oxy androgens in the liver and the placenta. State-of-the-art high-resolution mass spectrometry platforms will be utilised to identify these novel metabolites and confirm the hypothesis. Significance of the proposed study: This project will advance our current knowledge on the downstream metabolism of the C11-oxy androgens and will characterise a novel steroid pathway in fetal biology, potentially important in human development in health and disease.

Original text from CORDIS.

Participants

Links

Data: CORDIS, © European Union